- Email: [email protected]
Erratum to “Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance” [Clin Microbiol Infect (2014) O188–O196]
ERRATUM
BACTERIOLOGY
Erratum to “Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance” [Clin Microbiol Infect (2014) O188–O196] M. J. Cohen, C. S. Block, A. E. Moses and R. Nir-Paz Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Centers, Jerusalem, Israel
Corresponding author: R. Nir-Paz, Department of Clinical, Microbiology and Infectious Diseases, Hadassah Hebrew University, Medical Centers, Jerusalem 91120, Israel E-mail: [email protected]
It is with regret that the Figures 2–4 published in the PDF version of this article were incorrect. The problem does not occur in the HTML version. The figures in the PDF version should appear as follow:
FIG. 2. Frequency distribution of antibiotic exposure in temporal relation to the index specimen date. Cases are on the right pyramid (green) and controls are on the left (blue). (a) Distribution of antipseudomonal carbapenems (imipenem/meropenem). X-axis ranges between 0 and 220 days. (b) Distribution of ertapenem. X-axis ranges between 0 and 45 days. (c) Distribution of ureidopenicillin antibiotics. X-axis ranges between 0 and 45 days. Clin Microbiol Infect 2015; 21: e65–e67 © 2015 The Authors Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases http://dx.doi.org/10.1016/j.cmi.2015.05.009 DOI of original article: http://dx.doi.org/10.1111/1469-0691.12362
e66
Clinical Microbiology and Infection, Volume 21 Number 9, September 2015
CMI
FIG. 3. Survival of patients and acquisition of resistant Pseudomonas aeruginosa (PA). (a) Kaplan–Meier survival curves. Cases (blue line) vs. controls (orange line); p-values are with borderline statistical significance depending on method: log-rank 0.026, Breslow 0.071, Tarone-Ware 0.046. (b) Acquisition of carbapenem-resistant ureidopenicillin-resistant PA (CRUR-PA) since index date (CRUS-PA, blue line; carbapenem-sensitive ureidopenicillin-sensitive PA, grey line; carbapenem-sensitive ureidopenicillin-resistant PA, dark blue line). All three curves are significantly different one from the other (p-value <0.05).
© 2015 The Authors Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, e65–e67
CMI
Cohen et al.
Ertapenem and Pseudomonas aeruginosa
e67
FIG. 4. Acquisition of carbapenem-resistant ureidopenicillin-resistant Pseudomonas aeruginosa (CRUR-PA) among carbapenem-resistant ureidopenicillin-susceptible PA (CRUS-PA) cases, according to the type of antibiotic exposure in a 6-month period. No antibiotic exposure prior to and after the index date, black line; antibiotic exposure only prior to the index date, orange line; antibiotic exposure only after the index date, blue line; antibiotic exposure before and after the index date, green line.
© 2015 The Authors Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, e65–e67
BACTERIOLOGY
Erratum to “Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance” [Clin Microbiol Infect (2014) O188–O196] M. J. Cohen, C. S. Block, A. E. Moses and R. Nir-Paz Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Centers, Jerusalem, Israel
Corresponding author: R. Nir-Paz, Department of Clinical, Microbiology and Infectious Diseases, Hadassah Hebrew University, Medical Centers, Jerusalem 91120, Israel E-mail: [email protected]
It is with regret that the Figures 2–4 published in the PDF version of this article were incorrect. The problem does not occur in the HTML version. The figures in the PDF version should appear as follow:
FIG. 2. Frequency distribution of antibiotic exposure in temporal relation to the index specimen date. Cases are on the right pyramid (green) and controls are on the left (blue). (a) Distribution of antipseudomonal carbapenems (imipenem/meropenem). X-axis ranges between 0 and 220 days. (b) Distribution of ertapenem. X-axis ranges between 0 and 45 days. (c) Distribution of ureidopenicillin antibiotics. X-axis ranges between 0 and 45 days. Clin Microbiol Infect 2015; 21: e65–e67 © 2015 The Authors Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases http://dx.doi.org/10.1016/j.cmi.2015.05.009 DOI of original article: http://dx.doi.org/10.1111/1469-0691.12362
e66
Clinical Microbiology and Infection, Volume 21 Number 9, September 2015
CMI
FIG. 3. Survival of patients and acquisition of resistant Pseudomonas aeruginosa (PA). (a) Kaplan–Meier survival curves. Cases (blue line) vs. controls (orange line); p-values are with borderline statistical significance depending on method: log-rank 0.026, Breslow 0.071, Tarone-Ware 0.046. (b) Acquisition of carbapenem-resistant ureidopenicillin-resistant PA (CRUR-PA) since index date (CRUS-PA, blue line; carbapenem-sensitive ureidopenicillin-sensitive PA, grey line; carbapenem-sensitive ureidopenicillin-resistant PA, dark blue line). All three curves are significantly different one from the other (p-value <0.05).
© 2015 The Authors Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, e65–e67
CMI
Cohen et al.
Ertapenem and Pseudomonas aeruginosa
e67
FIG. 4. Acquisition of carbapenem-resistant ureidopenicillin-resistant Pseudomonas aeruginosa (CRUR-PA) among carbapenem-resistant ureidopenicillin-susceptible PA (CRUS-PA) cases, according to the type of antibiotic exposure in a 6-month period. No antibiotic exposure prior to and after the index date, black line; antibiotic exposure only prior to the index date, orange line; antibiotic exposure only after the index date, blue line; antibiotic exposure before and after the index date, green line.
© 2015 The Authors Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, e65–e67